Metastasis-related miR-185 is a potential prognostic biomarker for hepatocellular carcinoma in early stage

Biomedicine and Pharmacotherapy

Volumn 67, Issue 5, 2013, Pages 393-398

  Zhi, Qiaoming ^a   Zhu, Junjie ^a,b   Guo, Xiaobo ^c   He, Songbing ^a   Xue, Xiaofeng ^a   Zhou, Jin ^a   Hu, Bo ^a   Li, Hongying ^a   Chen, Shaoji ^a   Zhao, Hong ^a   Kuang, Yuting ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Metastasis related; MiR 185; Prognostic biomarker

Indexed keywords

ALANINE AMINOTRANSFERASE; MICRORNA; MICRORNA 185; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CARCINOMA CELL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SEX DIFFERENCE; TUMOR DIFFERENTIATION; TUMOR INVASION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84878354625     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.03.022     Document Type: Article

References (27)

1. Schutte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009, 27:80-92.
2. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491.
3. Sato M., Tateishi R., Yasunaga H., Horiguchi H., Yoshida H., Matsuda S., et al. Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol 2012, 47:1125-1133.
4. Niu D., Feng H., Chen W.N. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery. J Proteomics 2010, 73:1283-1290.
5. Jackson RJ, Standart N. How do microRNAs regulate gene expression? Sci STKE re1,2007.
6. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
7. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
8. Gailhouste L., Ochiya T. Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma. Histol Histopathol 2013, 28:437-451.
9. Borel F., Konstantinova P., Jansen P.L. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012, 56:1371-1383.
10. Srivastava K., Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One 2012, 7:e50966.
11. Wu W., Sun M., Zou G.M., Chen J. MicroRNA cancer: Current status prospective. Int J Cancer 2007, 120:953-960.
12. Gottardo F., Liu C.G., Ferracin M., Calin G.A., Fassan M., Bassi P., et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007, 25:387-392.
13. Yao Y., Suo A.L., Li Z.F., Liu L.Y., Tian T., Ni L., et al. MicroRNA profiling of human gastric cancer. Mol Med Report 2009, 2:963-970.
14. Takahashi Y., Forrest A.R., Maeno E., Hashimoto T., Daub C.O., Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 2009, 4:e6677.
15. Greenberg E., Hershkovitz L., Itzhaki O., et al. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 2010, 6:e18936.
16. Imam J.S., Buddavarapu K., Lee-Chang J.S., Ganapathy S., Camosy C., Chen Y., et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 2010, 29:4971-4979.
17. Tang H., Wang Z., Liu X., Liu Q., Xu G., Li G., et al. LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Curr Cancer Drug Targets 2012, 12:1032-1042.
18. Zhang Z., Tang H., Wang Z., Zhang B., Liu W., Lu H., et al. MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer 2011, 10:124.
19. Akcakaya P., Ekelund S., Kolosenko I., Caramuta S., Ozata D.M., Xie H., et al. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol 2011, 39:311-318.
20. Liu M., Lang N., Chen X., Tang Q., Liu S., Huang J., et al. miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells. Cancer Lett 2011, 301:151-160.
21. Budhu A., Jia H.L., Forgues M., Liu G.G., Goldstein D., Lam A., et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47:897-907.
22. Fujita N., Aishima S., Iguchi T., Mano Y., Taketomi A., Shirabe K. Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma. Hum Pathol 2011, 42:1531-1538.
23. Wakai T., Shirai Y., Nomura T., Nagakura S., Hatakeyyama K., et al. Computed tomographic features of hepatocellular carcinoma predict long-term survival after hepatic resection. Eur J Surg Oncol 2002, 28:235-242.
24. Shindoh J., Andreou A., Aloia T.A., Zimmitti G., Lauwers G.Y., Laurent A., et al. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol 2013, 20:1223-1229.
25. Lin M.C., Wu C.C., Cheng S.B., Liu T.J., Peng F.K. The influence of high serum testosterone levels on the long-term prognosis in male patients undergoing hepatectomy for early stage hepatocellular carcinoma without vascular invasion. World J Surg 2007, 31:1469-1473.
26. Ko E., Kim Y., Kim S.J., Joh J.W., Song S., Park C.K., et al. Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17:2260-2267.
27. Yanokura M., Banno K., Kobayashi Y., Kisu I., Ueki A., Ono A., et al. MicroRNA and endometrial cancer: roles of small RNAs in human tumors and clinical applications (Review). Oncol Lett 2010, 1:935-940.